Telehealth marketing that survives review: Meta and Google rules, HIPAA-safe tracking, the FDA GLP-1 crackdown, creators, and what an agency delivers.
The short answer
Telehealth marketing in 2026 is constrained on three sides: platform health policies that limit claims and targeting, HIPAA rules that limit what your pixel and audiences may contain, and, for weight-management providers, an FDA crackdown on compounded GLP-1 claims. What works is program-led creative, HIPAA-safe conversion tracking, local and condition-neutral search, and creators briefed from an approved claims sheet.
Key takeaways
Telehealth companies market a regulated service through platforms that treat health as a restricted category, and then track the results through systems that were not built for protected health information. Most telehealth marketing problems come from one of those two seams, and the third, the FDA, arrives by letter.
This page covers what a telehealth marketing strategy looks like when it is built to survive: channel by channel rules, HIPAA-compliant Google Ads and Meta tracking, the compounded GLP-1 enforcement wave, creator programs, and what to expect from a telehealth marketing agency.
Service-plus-place and service-plus-need searches ("online dermatologist", "telehealth for UTI", "weight loss program near me") convert best and clear review when the landing page describes the service. Google requires certification for certain healthcare advertisers and prohibits offering prescription drugs without a prescription as an egregious violation. Some healthcare targeting options are restricted.
Allowed for telehealth services with treat-or-manage framing, no personal-attribute copy, no before-and-after, no health-condition custom audiences. Meta has restricted lower-funnel optimization for health advertisers and disables health-coded events and audiences.
Prescription medicine ads are prohibited through self-serve in most markets, and weight content is age-gated with strict claim rules. Organic and creator content remains open.
Open on contextual placement, with publisher review. Often the largest media line for telehealth weight programs.
Email and SMS to patients are governed by HIPAA and consent, not by ad policy. They are the highest-return channel once the panel exists.
HIPAA does not ban telehealth advertising. It governs what protected health information leaves your systems, which in practice means your pixel, your conversions API, your audiences and your URL parameters.
A pixel firing on a post-consultation page sends the page URL, which names the condition. A custom audience built from "GLP-1 patients" is protected health information by its label. A conversion event named "Semaglutide purchase" is both a HIPAA problem and a Meta policy problem, and Meta disables those events anyway.
Consent captured before any marketing tag fires. Events named by funnel stage (lead, booked, started) with no condition or drug terms. No tracking on authenticated patient pages. Server-side event filtering that strips health terms from URLs and parameters. Audiences built from marketing engagement, never from clinical status. Business associate agreements where a vendor touches PHI, and a clear-eyed acceptance that the big ad platforms will not sign one, which is why nothing protected may reach them.
Beyond the legal exposure, a health-coded setup gets its events disabled and its campaigns unable to optimize. Clean naming is a performance decision as much as a compliance one.
On 3 March 2026 the FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products, the second batch since it began a crackdown on direct-to-consumer drug advertising in September 2025. Further letters followed in June 2026. The FDA's guidance for telehealth companies, updated June 2026, names the claims: implying sameness with an FDA-approved drug, describing a compounded drug as generic, claiming FDA approval or evaluation, "clinically proven" sameness claims, "FDA-approved" or "FDA-licensed" pharmacy sourcing claims, and branding that implies the telehealth company is the compounder.
The FDA reviews the website along with the ad. A telehealth marketing team can clear Meta review with a careful ad and still be the reason the company receives a letter, because the landing page, the FAQ or the checkout says what the ad avoided. Companies have fifteen business days to respond.
For a telehealth provider offering GLP-1 programs, the practical rule is a single claims sheet that governs the site, the ads, the emails and the creators, with medical review of every script. The weight loss advertising guide has the platform-by-platform detail and side-by-side examples.
Telehealth converts on trust, and trust is built by showing the care model rather than promising the result.
Who sees you, what they are licensed to do, how a consultation runs. The single most effective format in the category and the easiest to clear.
The app, the check-in cadence, what happens after the first visit, what it costs. Screen recordings and plain narration.
Who qualifies, which states, how prescriptions are issued and dispensed. Stated plainly, this is also what the FDA wants to see.
Real patients describing the experience of care, not outcomes, with written consent and disclosure. Side effects stated plainly read as credible.
Monthly cost, what is included, what is not. A page that answers this ranks and converts.
Twenty to thirty of these live at a time, refreshed weekly, is what holds paid performance. Four concepts for a quarter is how cost per booked consult climbs while everyone blames the platform.
Creators sell telehealth because a person describing a visit is more persuasive than a clinic describing itself. The rules stack up here: FTC disclosure and substantiation, platform health policies, HIPAA if the creator is a patient, and the FDA if the program involves medication.
Run it the way regulated creator programs have to run. Screen creators for claims history and disclosure habits before booking. Contract the approved lines verbatim and the banned words including synonyms. Medical review of every script before filming. Disclosure in the video as well as the caption. Frame-by-frame review of the delivered cut, including on-screen text and captions. Monitoring after posting and a takedown clause. Written releases where the creator is or plays a patient.
What a creator can say: they joined a program, what the consultation was like, how check-ins work, what it costs, that it is a paid partnership. What they cannot: outcome numbers, that a compounded drug equals a brand drug, that anything is FDA-approved when it is not, anything about the viewer's body. The influencer marketing compliance guide has the full process, and our influencer agent page shows how Remy runs it.
QuickAds is the creative and creator layer for telehealth marketing, not a HIPAA consultancy or a law firm. Your counsel and privacy officer own the claims sheet, the consent flow and the business associate agreements. We build inside them: clinician explainers, program walkthroughs, eligibility and pricing content and patient-experience video at volume, from a locked claims library, reviewed frame by frame, with event and audience naming that keeps health terms out of the ad platforms.
Remy, our influencer agent, sources, screens, negotiates and briefs creators, routes scripts to your medical reviewer, and delivers cuts already checked against the claims sheet. Creative intelligence trained on 32M+ ads reads which formats and hooks are working in telehealth now. Output runs 100+ creatives a month on a 5 to 7 day turnaround, and we run or coordinate programmatic through DSP partners where the plan needs it.
A managed program runs $2,000 to $5,000 per month depending on scope; software from $299 per month, and how the engagement runs is on its own page. Related: weight loss advertising, med spa marketing, LegitScript certification.
Telehealth marketing is the promotion of remote medical services under three overlapping constraints: ad platform health policies that limit claims, targeting and imagery; HIPAA rules that limit what patient information may reach pixels, audiences and ad platforms; and FDA and FTC rules on drug and health claims. Effective telehealth marketing describes the care model, eligibility and price rather than promising outcomes.
Yes, with a deliberate setup. Capture consent before marketing tags fire, name conversion events by funnel stage with no condition or drug terms, keep tracking off authenticated patient pages, strip health terms from URLs and parameters server-side, and build audiences from marketing engagement rather than clinical status. Google and Meta will not sign business associate agreements, so no protected health information may reach them.
It can describe the program: licensed clinicians, how consultations and check-ins work, eligibility, pricing, and that medication is prescribed only if clinically appropriate. It cannot promise outcomes, show before-and-after bodies, use second-person health copy, compare a compounded drug to a brand-name drug, or claim FDA approval or FDA-approved pharmacy sourcing. The FDA cited those claims in 30 warning letters in March 2026.
A telehealth marketing agency typically runs search and paid social campaigns, landing pages, HIPAA-conscious tracking, content and creative, and sometimes creator programs. Ask how it names events and audiences, whether it has handled compounded GLP-1 claims since the FDA's 2025 and 2026 letters, how many compliant creative concepts it ships monthly, and who reviews scripts medically before anything films or posts.
As an organic and creator channel, yes. As a paid channel, mostly no: TikTok prohibits prescription medicine ads through self-serve in most markets and applies strict age-gating and claim rules to weight content. Telehealth brands that succeed on TikTok run clinician explainers and disclosed patient-experience content organically, then use Spark Ads to boost posts that have already performed, with the same claim rules applied.
HIPAA-compliant digital advertising is running paid campaigns so that no protected health information reaches ad platforms, pixels or audiences. In practice: consent before marketing tags fire, conversion events named by funnel stage with no condition or drug terms, no tracking on authenticated patient pages, health terms stripped from URLs server-side, and audiences built from marketing engagement rather than clinical status. Google and Meta do not sign business associate agreements, so the data must never get there.